Treatment preferences for primary membranous nephropathy: Results of a multinational survey among nephrologists in the South Asia Pacific region.

Abstract

AIM\nThere is no clear consensus on how best to treat primary membranous nephropathy. This study aimed to ascertain prevailing views among nephrologists on their choice of immunosuppressive agents to treat this disease.\n\n\nMETHODS\nThe Australasian Kidney Trials Network conducted a multinational online survey among nephrologists from the South Asia-Pacific region to identify prescribing practices to treat primary membranous nephropathy. Survey questions focused on the types of immunosuppressive therapies used, preferred first-line and second-line therapies, indications for starting immunosuppressive therapy, the preferred mode of combining corticosteroid and cyclophosphamide, the use of serum phospholipase A2 receptor antibody testing in clinical practice, indications for anticoagulation, and interest in participating in future clinical trials in primary membranous nephropathy.\n\n\nRESULTS\n155 nephrologists from 8 countries responded to the online survey. The majority of them were senior nephrologists from Australia and India with significant experience managing patients with primary membranous nephropathy. The combination of cyclophosphamide and corticosteroid was the preferred first-line therapy. Of those who used this combination, only 34.8% followed the Kidney Disease Improving Global Outcomes (KDIGO) 2012 guidelines by adding intravenous methylprednisolone. The combination of calcineurin inhibitor with corticosteroid was the most common second-line therapy. Most respondents considered prophylactic anticoagulation if serum albumin was less than 25gm/L. Most nephrologists were keen to participate in a clinical trial with a control arm consisting of cyclophosphamide and corticosteroids.\n\n\nCONCLUSION\nThe combination of corticosteroid with cyclophosphamide (without intravenous methylprednisolone) is the most commonly reported first-line immunosuppressive therapy for the management of primary membranous nephropathy. This article is protected by copyright. All rights reserved.